Loading…
The acquisition is pending finalization of definitive agreements.
Scinai Immunotherapeutics Ltd. (XNAS: SCNI) announced its potential acquisition of Pincell S.r.l., a company specializing in cell therapy technologies. The transaction is subject to the finalization of definitive agreements.
No financial details or share considerations were disclosed in the announcement. The acquisition aims to enhance Scinai's capabilities in the biotechnology sector.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.